Inherited thrombocytopenia associated with a variant in the FLI1 binding site in the 5′ UTR of ANKRD26

Abstract

AbstractVariants in the 5′ UTR of ANKRD26 are a common cause of inherited thrombocytopenia (ANKRD26‐RT), and are associated with sustained ANKRD26 expression, which inhibits megakaryocyte maturation and proplatelet formation. ANKRD26 expression is controlled by the binding of a RUNX1/FLI1 complex to the 5′ UTR. To date, all reported ANKRD26‐RD associated variants have been within the RUNX1 binding site and a 22 base pair flanking region. Here, we report a novel variant in the 5′ UTR of ANKRD26, c.‐107C>T. This variant is in the FLI1 binding site, and is predicted to disrupt FLI1 binding due to loss of a hydrogen bond with FLI1. Differentiated PBMCs from affected family members showed impaired megakaryocyte maturation and proplatelet formation and sustained expression of ANKRD26, and platelets from affected family members had higher ANKRD26 expression than control platelets. The variant increased activity of the ANKRD26 promotor in a reporter assay. We also provide evidence that the previously reported c.‐140C>G ANKRD26 5′ UTR variant is benign and not associated with thrombocytopenia. Identification of the c.‐107C>T variant extends the range of the regulatory region in the 5′ UTR of ANKRD26 that is associated with ANKRD26‐RT.